+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The presence of Muellerian inhibiting substance in human seminal plasma



The presence of Muellerian inhibiting substance in human seminal plasma



Human Reproduction 11(10): 2165-2169



Muellerian inhibiting substance (MIS), produced by testicular Sertoli cells, is present in adult male serum. The first aim of this study was to determine if MIS is present in seminal plasma. Using an enzyme-linked immunosorbent assay (ELISA), we measured MIS concentrations in seminal plasma from 23 donors exhibiting normal (WHO criteria) sperm qualities, and 169 patients with subnormal sperm parameters. The second aim of this study was to examine a potential relationship between MIS and sperm motility. MIS concentrations in seminal plasma ranged from 0.5 to 3.6 ng/ml in donors and from 0.5 to 17.8 ng/ml in patients. Motility index (MI, mean +- SEM) for all patient samples was lower compared with donors (113.3 +- 3.2 and 198.3 +- 13.5, P lt 0.00001), while mean MIS concentration (t SEM) was higher (4.2 +- 0.3 and 1.4 +- 0.2, P lt 0.0003). When the patients were stratified into Groups I (motility lt 50%, n = 42) and II (motility gt 50%, n = 127), the MI (mean +- SEM) values were 62.3 +- 3.8 and 130.2 +- 2.7 respectively (P lt 0.0001 for both compared with donors) and mean MIS concentrations (+- SEM) were 5.4 +- 0.6 and 3.9 +- 0.3, respectively (P lt 0.0001 and P lt 0.001 compared with donors). The inverse relationship between MIS concentration in seminal plasma and motility index suggests that MIS may have a function in modulating motility.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009609527

Download citation: RISBibTeXText

PMID: 8943523


Related references

Andrology: The presence of Mullerian inhibiting substance in human seminal plasma. Human Reproduction 11(10): 2165-2169, 1996

Insensitivity of the chick embryo muellerian duct to human recombinant muellerian inhibiting substance. Journal of Molecular Endocrinology 8(1): 73-78, 1992

Antibody against avian muellerian inhibiting substance mis recognizes mis on rat muellerian duct and human tumor cells. Proceedings of the National Science Council Republic of China Part B Life Sciences 13(4): 267-275, 1989

Studies on interleukin 2 inhibiting substance in human seminal plasma. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 78(4): 614-625, 1987

Programmed cell death in the muellerian duct induced by muellerian inhibiting substance. American Journal of Anatomy 149(3): 353-376, 1977

The correlation of glycolization in muellerian inhibiting substance and its activity for muellerian duct regression. Journal Of Cell Biologypart 2: 38a, 1983

Involution of the muellerian duct under the influence of the muellerian inhibiting substance in an organ culture assay. Anatomical Record 193(3): 657-658, 1979

Isolation of the bovine and human genes for muellerian inhibiting substance and expression of the human gene in animal cells. Cell 45(5): 685-698, 1986

Human muellerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Research 51(8): 2101-2106, 1991

The binding of muellerian inhibiting substance mis and growth hormone gh on chick muellerian duct md corresponds to ductal regression and growth. Journal of Cell Biology 105(4 Part 2): 12A, 1987

Muellerian inhibiting substance blocks autophosphorylation of the egf receptor by inhibiting tyrosine kinase. Molecular and Cellular Endocrinology 49(1): 75-86, 1987

Muellerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay. Gynecologic Oncology 22(2): 135-148, 1985

Muellerian inhibiting substance inhibition of a human endometrial carcinoma cell line xeno grafted in nude mice. Gynecologic Oncology 17(1): 124-132, 1984

Interaction of seminal plasma proteins with cell surface antigens: presence of a CD4-binding glycoprotein in human seminal plasma. Experimental Cell Research 197(2): 268-271, 1991

Prolactin (PRL) inhibiting substance in seminal plasma of infertile patients. Preliminary results. Acta Europaea Fertilitatis 17(3): 207-211, 1986